Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures

Acta Diabetologica

Volumn 49, Issue 1, 2012, Pages 75-79

  Davalli, Alberto M ^a   Perego, Carla ^b   Folli, Franco B ^c   Bosi, Emanuele ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Remission phase; Topiramate; Type 1 diabetes (T1D)

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; OXCARBAZEPINE; PANCREAS ISLET CELL ANTIBODY; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE;

ADULT; ARTICLE; BODY MASS; CASE REPORT; CLINICAL FEATURE; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GRAND MAL SEIZURE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; KETONURIA; MAINTENANCE DRUG DOSE; MALE; ORAL GLUCOSE TOLERANCE TEST; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; REMISSION; WEIGHT REDUCTION; SEIZURE;

ADULT; ANTICONVULSANTS; DIABETES MELLITUS, TYPE 1; FRUCTOSE; HUMANS; MALE; REMISSION INDUCTION; SEIZURES;

EID: 84861700104     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-011-0268-y     Document Type: Article

References (28)

1. Aly H, Gottlieb P (2009) The honeymoon phase: intersection of metabolism and immunology. Curr Opin Endocrinol Diabetes Obes 16(4):286-292
2. Bonfanti R, Bazzigaluppi E, Calori G, Riva MC, Viscardi M, Bognetti E, Meschi F, Bosi E, Chiumello G, Bonifacio E (1998) Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Diabet Med 15(10):844-850
3. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop. Diabetes 53:250-264 (Pubitemid 38044724)
4. DCCT Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 128:517-523
5. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2008) Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention, draft guidance. http://www.fda.gov/cder/guidance/7630dft.pdf
6. Calcaterra V, Bottazzi A, Tzialla C, D'Arrigo S, Larizza D (2011) Iatrogenic diabetes mellitus during ACTH therapy in an infant with West syndrome. Acta Diabetol. doi:10.1007/s00592-011-0253-5
7. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M (2004) A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes 28(11):1399-1410 (Pubitemid 39481843)
8. Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M (2007) Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes 31(1):138-146 (Pubitemid 46006027)
9. Stenlöf K, Rössner S, Vercruysse F, Kumar A, Fitchet M, Sjöström L (2007) Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 9(3):360-368
10. Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A (2007) A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 30(6):1480-1486 (Pubitemid 46871158)
11. Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ (2008) Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 51(5):846-852
12. Rolandsson O, Palmer JP (2010) Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes! Diabetologia 53(7):1250-1253
13. Jin P, Huang G, Lin J, Luo S, Zhou Z (2011) Epitope analysis of GAD65 autoantibodies in adult-onset type 1 diabetes and latent autoimmune diabetes in adults with thyroid autoimmunity. Acta Diabetol. doi:10.1007/s00592-010-0250-0
14. Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, Vicari AM (1988) Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 318(16):1012-1020 (Pubitemid 18095005)
15. Olson JA, Olson DM, Sandborg C, Alexander S, Buckingham B (2002) Type 1 diabetes mellitus and epilepsia partialis continua in a 6-year-old boy with elevated anti-GAD65 antibodies. Pediatrics 109(3):E50
16. McCorry D, Nicolson A, Smith D, Marson A, Feltbower RG, Chadwick DW (2006) An association between type 1 diabetes and idiopathic generalized epilepsy. Ann Neurol 59(1):204-206 (Pubitemid 43042891)
17. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Dotta F, Bosi E (2007) High titre of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 30:932-938 (Pubitemid 46556589)
18. Bottazzo GF, Bosi E, Cull CA, Bonifacio E, Locatelli M, Zimmet P, Mackay IR, Holman RR (2005) IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 48:703-708 (Pubitemid 40591226)
19. Liang Y, Chen X, Osborne M, DeCarlo SO, Jetton TL, Demarest K (2005) Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice. Diabetes Obes Metab 7(4):360-369 (Pubitemid 40916578)
20. Frigerio F, Chaffard G, Berwaer M, Maechler P (2006) The antiepileptic drug topiramate preserves metabolism-secretion coupling in insulin secreting cells chronically exposed to the fatty acid oleate. Biochem Pharmacol 72(8):965-973 (Pubitemid 44374464)
21. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M (2004) The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45(7):737-744 (Pubitemid 38890970)
22. Gray SG, De Meyts P (2005) Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab Res Rev 21(5):416-433 (Pubitemid 41320653)
23. Larsen L, Tonnesen M, Ronn SG, Størling J, Jørgensen S, Mascagni P, Dinarello CA, Billestrup N, Mandrup-Poulsen T (2007) Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia 50(4):779-789 (Pubitemid 46355819)
24. Haumaitre C, Lenoir O, Scharfmann R (2008) Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors. Mol Cell Biol 28(20):6373-6383
25. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, Li B, Turka LA, Olson EN, Greene MI, Wells AD, Hancock WW (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13(11):1299-1307 (Pubitemid 350073591)
26. Li B, Samanta A, Song X, Iacono KT, Bembas K, Tao R, Basu S, Riley JL, Hancock WW, Shen Y, Saouaf SJ, Greene MI (2007) FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA 104(11):4571-4576 (Pubitemid 47186266)
27. Luo X, Herold KC, Miller SD (2010) Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 32(4):488-499
28. Matthews JB, Staeva TP, Bernstein PL, PeakmanM, von Herrath M (2010) ITN-JDRF Type 1 diabetes combination therapy assessment group.Developing combination immunotherapies for type 1 diabetes: recommendations fromthe ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 160(2):176-184